Quest Diagnostics announced that its board of directors elected James Davis, the company’s CEO and president, to serve in the additional position of chairman of the board of directors, effective April 1. Davis, who joined the company in 2013 and assumed the role of CEO, president and director on November 1, 2022, will succeed former CEO Steve Rusckowski, who remains chairman through March 31.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics enters multi-year agreement with Tower Health
- Quest Diagnostics to acquire select assets of NYP laboratory services business
- Quest Diagnostics and NewYork-Presbyterian Agree to Laboratory Services Transaction
- Quest Diagnostics raises quarterly dividend, increases share repurchase program
- Quest Diagnostics sees FY23 adjusted EPS $8.40-$9.00, consensus $8.69